Introduction to high-performance liquid chromatography-tandem mass spectrometry: The gold standard for monitoring immunosuppressive drugs
P. J. TaylorAnn Transplant 2008; 13(1): 18-18 :: ID: 880172
Abstract
Many of the immunosuppressive drugs require monitoring to provide optimal and individualised therapy for patients who have undergone solid organ transplantation. Clinical laboratories have the choice of methodology used for these drug analyses and this choice may impact on the quality of pharmacokinetic data provided to the transplant physician. The majority of laboratories use either high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) or antibody-based immunoassays. Most of the measured immunosuppressive drugs are neutral in nature and would appear unsuited to the ionisation processes of HPLC-MS/MS. However, ionisation of these compounds can be achieved by the addition of modifiers, such as
ammonium acetate, to the mobile phase which promote adduct formation. The use of successive (tandem) mass analysers provides for high selectivity and sensitivity which is required for the measurement of the more potent drugs (i.e. tacrolimus, sirolimus and everolimus) and simplifies the chromatographic separation. Thus making this technique highly suited to the clinical requirements for monitoring these drugs. While immunoassays are widely used for analysis of immunosuppressive drugs, there are several drawbacks to their use. Firstly, these methods tend to suffer from over-estimation in results due to the non-specific binding (to varying degrees) of metabolites with the assay antibody and have been shown to be influenced by the biochemical status of the patient, such as hematocrit. Secondly, some immunoassays have been shown to have poor accuracy and imprecision at the critical lower end of the therapeutic range. The aims of this presentation are to provide an overview on HPLC-MS/MS instrumentation, to discuss its use in the therapeutic drug monitoring of immunosuppressive drugs, and to provide a critical comparison with immunoassays.
Keywords: immunosuppressive drugs, Organ Transplantation, Bladder, cystofix, knotting.
In Press
06 May 2022 : Original article
Phosphatidylethanol (PEth) for Monitoring Sobriety in Liver Transplant Candidates: Preliminary Results of D...Ann Transplant In Press; DOI: 10.12659/AOT.936293
27 Apr 2022 : Review article
A Systematic Review of the Literature on Chronic Kidney Disease Following Liver TransplantationAnn Transplant In Press; DOI: 10.12659/AOT.935170
Most Viewed Current Articles
31 Dec 1969 : Original article
Efficacy and Safety of Tacrolimus-Based Maintenance Regimens in De Novo Kidney Transplant Recipients: A Sys...DOI :10.12659/AOT.933588
Ann Transplant 2021; 26:e933588
31 Dec 1969 : Review article
Recurrence of Hepatocellular Carcinoma After Liver Transplantation: Risk Factors and Predictive ModelsDOI :10.12659/AOT.934924
Ann Transplant 2022; 27:e934924
31 Dec 1969 : Review article
Kidney Transplantation in the Times of COVID-19 – A Literature ReviewDOI :10.12659/AOT.925755
Ann Transplant 2020; 25:e925755
31 Dec 1969 : Case report
Combined Liver, Pancreas-Duodenum, and Kidney Transplantation for Patients with Hepatitis B Cirrhosis, Urem...DOI :10.12659/AOT.935860
Ann Transplant 2022; 27:e935860